Karen Aiach
PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Lysogene (Paris:LYS) (FR0013233475 – LYS), a leading clinical-stage biopharmaceutical company specializing in gene therapy technology applied to central nervous system diseases, announced today that Karen Aiach, CEO and Founder of Lysogene, won the Women’s Entrepreneurship’s Innovation & New Technologies Trophy - co-organized by the Women’s Entrepreneurship Association and the CPME - rewarding her “spectacular breakthrough in the exclusive arena of rare diseases.”
On Thursday 11th, during the prestigious ceremony held at the Economic, Social and Environmental Counsel in Paris, and hosted by François Asselin, Chairman of CPME, the jury rewarded an « entrepreneurial mother’s tenacity » and applauded that a “family issue turned into a medical research and entrepreneurial goal”.
According to François Asselin, « these trophies highlight talented, resourceful, bold and tough female directors who launch and establish their companies abroad in order to promote the entrepreneurship “à la française”.”
“I am greatly touched by this reward. I dedicate it to children suffering from rare diseases and their families, as well as to my own team and shareholders who believe in Lysogene” said Karen Aiach. “I am proud to run a company where diversity goes without saying. I will always fight so that women occupy the place they deserve in the business world.”
About the Women’s Entrepreneurship Association
About CPME
The CPME – French Small and Mid-Caps Confederation – is a private, independent, inter-branch employer organization, whose representativeness is officially accepted. It ensures all sectored - industry, trades, services, craftsmanship - small and mid-caps’ representation and defense, both at national level – alongside public authorities and social partners - and international level. It simultaneously gathers professional federations, trade unions and territorial structures.
For more information: http://www.cpme.fr/
About Lysogene
